Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting share prices for British biotechs across its portfolio in December. The London-based company ended 2022 with net assets of £1.29 billion ($1.55 billion) compared with £1.36 billion ($1.63 billion) at the end of September, marking a 5.1% drop in net asset value (NAV) return. Source: Fierce Biotech 7/2/2023